Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Yu-Ning Wong

Email
Center AffiliationsCancer Prevention and Control

Publications (115) (print view)

paginate
Egleston BL, Uzzo RG, Wong YN. Latent Class Survival Models Linked by Principal Stratification to Investigate Heterogenous Survival Subgroups Among Individuals With Early-Stage Kidney Cancer. Journal of the American Statistical Association. 2017 Jan;112(518):534-46.
Jayadevappa R, Chhatre S, Wong YN, Wittink MN, Cook R, Morales KH, Vapiwala N, Newman DK, Guzzo T, Wein AJ, Malkowicz SB, Lee DI, Schwartz JS, Gallo JJ. Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant). Medicine (United States). 2017 Jan;96(18).
Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE, Viterbo R, Geynisman DM, Kutikov A, Plimack ER, Smaldone MC, Wong YN, Bilusic M. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clin Genitourin Cancer. 2017 Sep 30;15(3):e337-e343.
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K, Young Academic Urologists-Urothelial Carcinoma Group-European Association of U, the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium g. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European urology focus. 2017 Jun 03;.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Retrospective International Study of Invasive/Advanced Cancer of the U. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2017 Mar 31;.
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, Risc Investigators. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 Feb;71(2):281-9.
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY, Risc Investigators. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer medicine. 2017 Jan;6(1):186-94.   PMCID: PMC5269690
Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, Kim SP, Malhotra A, Handorf E, Wong YN, Uzzo RG, Kutikov A. Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. Med Care. 2017 Apr;55(4):398-404.   PMCID: PMC5352513
Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong YN, Patel SA, Boraas M, Chang EI, Topham NS, Egleston BL. Time to Surgery and Breast Cancer Survival in the United States. JAMA Oncol. 2016 Mar;2(3):330-9.   PMCID: 4788555
Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong YN, Patel SA, Boraas M, Chang EI, Topham NS, Egleston BL. Time to Surgery and Breast Cancer Survival in the United States. JAMA Oncol. 2016 Mar;2(3):330-9.   PMCID: PMC4788555
Geynisman DM, Handorf E, Wong YN, Doyle J, Plimack ER, Horwitz EM, Canter DJ, Uzzo RG, Kutikov A, Smaldone MC. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer medicine. 2016 Feb;5(2):192-9.   PMCID: 4735777
Geynisman DM, Wong YN. Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?. JAMA Oncol. 2016 Mar;2(3):295-6.
Geynisman DM, Wong YN. Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?. JAMA Oncol. 2016 Mar;2(3):295-6.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 Mar 08;387(10032):2008-16.   PMCID: 4878938
Kircher SM, Meeker CR, Nimeiri H, Geynisman DM, Zafar SY, Shankaran V, de Souza J, Wong YN. The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?. Value Health. 2016 Jan;19(1):88-98.
Li P, Wong YN, Armstrong K, Haas N, Subedi P, Davis-Cerone M, Doshi JA. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer medicine. 2016 Feb;5(2):169-81.   PMCID: PMC4735783
Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN. Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract. 2016 Jun 21;12(7):e755-64.   PMCID: PMC5015446
Meropol NJ, Wong YN, Albrecht T, Manne S, Miller SM, Flamm AL, Benson AB, Buzaglo J, Collins M, Egleston B, Fleisher L, Katz M, Kinzy TG, Liu TM, Margevicius S, Miller DM, Poole D, Roach N, Ross E, Schluchter MD. Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol. 2016 Feb 10;34(5):469-78.   PMCID: PMC4872012
Miron B, Ristau BT, Tomaszewski JJ, Jones J, Milestone B, Wong YN, Uzzo RG, Edmondson D, Scott W, Kutikov A. Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer. Urol Case Rep. 2016 Nov;9:9-11.   PMCID: PMC5011172
Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016 Aug;34(27):3308-14.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2016 Dec;68(6):959-67.
Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY, Retrospective International Study of Cancers of the Urothelium I. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2016 Sep 16;.
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1317-24.
Rose TL, Deal AM, Ladoire S, Crehange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI. Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2016 Oct 27;2(4):405-13.   PMCID: PMC5181658
Vachani A, Wong YN, Israelite J, Mitra N, Hin S, Yang L, Smith-McLallen A, Armstrong K, Groeneveld PW, Epstein AJ. Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care. 2016 Jan 22;.
Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer. 2016 Oct 15;122(20):3191-8.   PMCID: PMC5048504
Wong YN, Roach N, Meropol NJ. Addressing Patients' Priorities as a Strategy to Improve Value. The oncologist. 2016 Oct 14;.   PMCID: PMC5189625
Wong YN, Schluchter MD, Albrecht TL, Benson AB, Buzaglo J, Collins M, Flamm AL, Fleisher L, Katz M, Kinzy TG, Liu TM, Manne S, Margevicius S, Miller DM, Miller SM, Poole D, Raivitch S, Roach N, Ross E, Meropol NJ. Financial Concerns About Participation in Clinical Trials Among Patients With Cancer. J Clin Oncol. 2016 Feb 10;34(5):479-87.   PMCID: PMC4872013
Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL. Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care. 2015 Sep;53(9):e65-72.   PMCID: 3818341
Barth P, Dulaimi Al-Saleem E, Edwards KW, Millis SZ, Wong YN, Geynisman DM. Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. Case Rep Oncol Med. 2015 Jan;2015:895151.   PMCID: Pmc4322830
Boland PM, Ruth K, Matro JM, Rainey KL, Fang CY, Wong YN, Daly MB, Hall MJ. Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing. Clinical Genetics. 2015 Dec 19;88(6):565-72.   PMCID: 4474774
Egleston BL, Pedraza O, Wong YN, Dunbrack RL, Griffin CL, Ross EA, Beck JR. Characteristics of clinical trials that require participants to be fluent in English. Clin Trials. 2015 Dec;12(6):618-26.   PMCID: 4643363
Egleston BL, Uzzo RG, Beck JR, Wong YN. A Simple Method for Evaluating Within Sample Prognostic Balance Achieved by Published Comorbidity Summary Measures. Health Serv Res. 2015 Aug;50(4):1179-94.   PMCID: 4545353
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong Y, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective Int Study Canc U. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Hoffman-Censits J, Wong YN. Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma. Clin Genitourin Cancer. 2015 Aug;13(4):302-8.   PMCID: 4504799
Knollman H, Godwin JL, Jain RI, Wong YN, Plimack ER, Geynisman DM. Muscle-invasive urothelial bladder cancer: An update on systemic therapy. Therapeutic Advances in Urology. 2015 Jan;7(6):312-30.   PMCID: 4647143
Manne S, Kashy D, Albrecht T, Wong YN, Flamm AL, Benson AB, Miller SM, Fleisher L, Buzaglo J, Roach N, Katz M, Ross E, Collins M, Poole D, Raivitch S, Miller DM, Kinzy TG, Liu T, Meropol NJ. Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers. European Journal of Cancer Care. 2015 Jan;24(1):28-38.
Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, Wong YN. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. Clin Breast Cancer. 2015 Feb;15(1):1-7.   PMCID: 4422394
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb;13(1):71-9.
Smaldone MC, Handorf E, Kim SP, Thompson RH, Costello BA, Corcoran AT, Wong YN, Uzzo RG, Leibovich BC, Kutikov A, Boorjian SA. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: An analysis of the national cancer database. Journal of Urology. 2015 Jan;193(4):1108-13.
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr;13(2):185-92.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, Blitzblau RC, Moy B, Breslin T, Edge SB, Hassett MJ, Punglia RS. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015 Nov;93(3):622-30.
Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. J Clin Oncol. 2015 May 11;33(20):2254-61.   PMCID: 4486344
Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. Clinical Genitourinary Cancer. 2015 Apr;13(2):142-9.
Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Invest New Drugs. 2015 Oct;33(5):1040-7.   PMCID: 4573837
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 2014 Apr;12(2):130-7.   PMCID: Pmc4142680
Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian Journal of Andrology. 2014 May;16(3):372-7.   PMCID: PMC4023362
Dotan E, Li T, Hall MJ, Meropol NJ, Beck JR, Wong YN. Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer. J Oncol Pract. 2014 Sep;10(5):308-14.   PMCID: Pmc4161728
Goldsack JC, Reilly C, Bush C, McElligott S, Bristol MN, Motanya UN, Field R, Vozniak JM, Wong YN, Schwartz JS, Domchek S. Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm. 2014 Apr;71(7):571-8.
Manne S, Kashy D, Albrecht T, Wong YN, Flamm AL, Benson AB, Miller SM, Fleisher L, Buzaglo J, Roach N, Katz M, Ross E, Collins M, Poole D, Raivitch S, Miller DM, Kinzy TG, Liu T, Meropol NJ. Knowledge, Attitudes, and Self-efficacy as Predictors of Preparedness for Oncology Clinical Trials: A Mediational Model. Medical Decision Making. 2014 May;34(4):454-63.   PMCID: PMC3991731
Matro JM, Ruth KJ, Wong YN, McCully KC, Rybak CM, Meropol NJ, Hall MJ. Cost Sharing and Hereditary Cancer Risk: Predictors of Willingness-to-Pay for Genetic Testing. Journal of Genetic Counseling. 2014 Dec;23(6):1002-11.   PMCID: 4420173
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin JQ, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology. 2014 Jun;32(18):1895-901.   PMCID: PMC 4050203
Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye [Letter]. J Clin Oncol. 2014 Dec 20;32(36):4171-2.
Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The oncologist. 2014 Apr;19(4):354-5.   PMCID: Pmc3983829
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU international. 2014 May;113(5B):E137-E143.
Silverman D, Ruth K, Sigurdson ER, Egleston BL, Goldstein LJ, Wong YN, Boraas M, Bleicher RJ. Skin involvement and breast cancer: are T4b lesions of all sizes created equal?. Journal of the American College of Surgeons. 2014 Sep;219(3):534-44.   PMCID: Pmc4143438
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer. Journal of Urology. 2014 Nov;192(5):1349-54.
Canter D, Egleston B, Wong YN, Smaldone MC, Simhan J, Greenberg RE, Uzzo RG, Kutikov A. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis. Urologic Oncology-Seminars and Original Investigations. 2013 Aug;31(6):866-70.
Crivello ML, Ruth K, Sigurdson ER, Egleston BL, Evers K, Wong YN, Boraas M, Bleicher RJ. Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population. Ann Surg Oncol. 2013 Jan;20(1):102-10.   PMCID: PMC3923372
de Souza JA, Wong YN. Financial Distress in Cancer Patients. J Med Person. 2013 Aug;11(2):73-7.   PMCID: PMC3859450
Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He YL, Wong YN, Theriault R, Keating NL. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer. 2013 Feb;119(4):839-46.   PMCID: PMC3565006
Mehrazin R, Wong YN, Wu H, Al-Saleem T, Smaldone M. Renal Cell Carcinoma Metastasis to a Contralateral Oncocytoma in a Patient Presenting With Bilateral Synchronous Renal Tumors. Clinical Genitourinary Cancer. 2013 Dec;11(4):E27-E29.
Stump TK, Eghan N, Egleston BL, Hamilton O, Pirollo M, Schwartz JS, Armstrong K, Beck JR, Meropol NJ, Wong YN. Cost concerns of patients with cancer. J Oncol Pract. 2013 Sep;9(5):251-7.   PMCID: Pmc3770507
Wong YN. Are oncologists' financial incentives aligned with quality care?. J Clin Oncol. 2013 Feb 10;31(5):517-9.   PMCID: PMC3500484
Wong YN, Egleston BL, Sachdeva K, Eghan N, Pirollo M, Stump TK, Beck JR, Armstrong K, Schwartz JS, Meropol NJ. Cancer Patients' Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting. Medical Care. 2013 Sep;51(9):838-45.   PMCID: PMC 3857689
Beach DF, Somer RA, Hoffman-Censits J, Lin J, Wong YN, Plimack E, Hudes G, Vaughn D, Bernstein GT, Morris GJ. A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer. Semin Oncol. 2012 Feb;39(1):1-8.
Bleicher RJ, Ruth K, Sigurdson ER, Ross E, Wong YN, Patel SA, Boraas M, Topham NS, Egleston BL. Preoperative Delays in the US Medicare Population With Breast Cancer. J Clin Oncol. 2012 Dec 20;30(36):4485-92.   PMCID: PMC 3518727
Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC. Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer. Journal of Clinical Oncology. 2012 Jun;30(18):2218-26.   PMCID: PMC3397718 [Available on 2013/6/20]
Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG. Competing Risks of Death in Patients with Localized Renal Cell Carcinoma: A Comorbidity Based Model. Journal of Urology. 2012 Dec;188(6):2077-83.
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov;118(22):5463-72.   PMCID: PMC 36116559
Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer. The oncologist. 2012 Jun;17(6):775-82.   PMCID: PMC3380876
Simhan J, Canter D, Teper E, Smaldone MC, Patil N, Patchefsky A, Guttmann MC, Milestone B, Wong YN, Hicks LA, Uzzo RG, Kutikov A. Adrenocortical carcinoma masquerading as a benign adenoma on computed tomography washout study. Urology. 2012 Feb;79(2):e19-20.   PMCID: not NIH funded
Stitzenberg KB, Wong YN, Nielsen ME, Egleston BL, Uzzo RG. Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer. 2012 Jan;118(1):54-62.   PMCID: PMC184376
Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Research and Treatment. 2012 Dec;136(3):813-21.   PMCID: PMC 3513497
Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. Journal of Clinical Oncology. 2012 Oct;30(28):3545-51.   PMCID: PMC3454772
Wong YN, Ward J, Neuss M. Response to payer coverage for patients enrolled onto clinical trials. J Oncol Pract. 2012 Nov;8(6):371-2.   PMCID: PMC3500484
Brewster AM, Etzel C, Zhou R, Wong Y, Edge S, Blayney DW, Wilson J, Hudis C, Ottesen R, Hughes ME, Weeks JC, Theriault RL. The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers. Breast Cancer Research and Treatment. 2011 Dec;130(3):897-904.   PMCID: NIHMS395682
Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F, Oblaczynski M, Berberian R, Chen DY, Greenberg RE, Uzzo RG, Boorjian SA. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology. 2011 Jan;77(1):160-5.   PMCID: publisher will deposit
Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong YN, Carter B, Javid S, Edge S, Burstein H, Golshan M. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Research and Treatment. 2011 Sep;129(2):459-65.   PMCID: PMC3382105
Klayton TL, Ruth K, Buyyounouski MK, Uzzo RG, Wong YN, Chen DY, Sobczak M, Peter R, Horwitz EM. PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition. Practical radiation oncology. 2011 Jan;1(4):235-42.   PMCID: PMC3197783
Kutikov A, Mallin K, Canter D, Wong YN, Uzzo RG. Effects of Increased Cross-Sectional Imaging on the Diagnosis and Prognosis of Adrenocortical Carcinoma: Analysis of the National Cancer Database. Journal of Urology. 2011 Sep;186(3):805-10.   PMCID: PMC3432982
Pollack CE, Bekelman JE, Epstein AJ, Liao KJ, Wong YN, Armstrong K. Racial Disparities in Changing to a High-volume Urologist Among Men With Localized Prostate Cancer. Medical Care. 2011 Nov;49(11):999-1006.   PMCID: PMC3298812
Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen JH, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer. 2011 Dec;47(18):2706-14.   PMCID: not NIH funded
Wong YN, Coups EJ. Correlates of Colorectal Cancer Screening Adherence Among Men Who have been Screened for Prostate Cancer. Journal of Cancer Education. 2011 Jun;26(2):301-7.   PMCID: PMC3098903
Wong YN, Ottesen RA, Hughes ME, Niland JC, Theriault R, Edge SB, Blayney D, Weeks JC. Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?. The oncologist. 2011 Jan;16(5):559-65.   PMCID: PMC3228199
Alderman AK, Collins ED, Schott A, Hughes ME, Ottesen RA, Theriault RL, Wong YN, Weeks JC, Niland JC, Edge SB. The Impact of Breast Reconstruction on the Delivery of Chemotherapy. Cancer. 2010 Apr;116(7):1791-800.   PMCID: PMC2847068 [Available on 2011/4/1]
Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram. Journal of Clinical Oncology. 2010 Jan;28(2):311-7.   PMCID: PMC2815719
Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU international. 2010 Jul;106(2):218-23.   PMCID: PMC2906619
Rajput A, Romanus D, Weiser MR, Ter Veer A, Niland J, Wilson J, Skibber JM, Wong YN, Benson A, Earle CC, Schrag D. Meeting the 12 Lymph Node (LN) Benchmark in Colon Cancer. Journal of Surgical Oncology. 2010 Jul;102(1):3-9.   PMCID: not NIH funded
Wong YN, Hamilton O, Egleston B, Salador K, Murphy C, Meropol NJ. Understanding How Out-of-Pocket Expenses, Treatment Value, and Patient Characteristics Influence Treatment Choices. The oncologist. 2010 Jan;15(6):566-76.   PMCID: PMCID: PMC2892556 [Available on 2011/1/1]
Earle CC, Weiser MR, Ter Veer A, Skibber JM, Wilson J, Rajput A, Wong YN, Benson AB, Shibata S, Romanus D, Niland J, Schrag D. Effect of Lymph Node Retrieval Rates on the Utilization of Adjuvant Chemotherapy in Stage II Colon Cancer. Journal of Surgical Oncology. 2009 Dec;100(7):525-8.   PMCID: not NIH funded
Egleston BL, Wong YN. Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data. Statistics in medicine. 2009 May;28(10):1498-511.   PMCID: PMC2741403
Min H, Manion FJ, Goralczyk E, Wong YN, Ross E, Beck JR. Integration of prostate cancer clinical data using an ontology. J Biomed Inform. 2009 Dec;42(6):1035-45.   PMCID: PMC2784120
Putt M, Long JA, Montagnet C, Silber JH, Chang VW, Liao KJ, Schwartz JS, Pollack CE, Wong YN, Armstrong K. Racial Differences in the Impact of Comorbidities on Survival Among Elderly Men With Prostate Cancer. Medical Care Research and Review. 2009 Aug;66(4):409-35.   PMCID: PMC2780425
Romanus D, Weiser MR, Skibber JM, Ter Veer A, Niland JC, Wilson JL, Rajput A, Wong YN, Benson AB, Shibata S, Schrag D. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: An NCCN Institutional Analysis. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):895-904.   PMCID: not NIH funded
Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox E, Uzzo RG. Pathologic Concordance of Sporadic Synchronous Bilateral Renal Masses. J Urol. 2009 Mar;181(3):1061-2.
Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological Characteristics of Localized Renal Cell Carcinoma Correlate With Tumor Size: A SEER Analysis. Journal of Urology. 2009 Jan;181(1):29-33.   PMCID: PMC2782573
Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, Tumor Size and Relative Survival of Patients With Localized Renal Cell Carcinoma: A Surveillance, Epidemiology and End Results Analysis. Journal of Urology. 2009 Feb;181(2):506-11.   PMCID: PMC 2703466
Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, Schrag D. Factors Associated With Sphincter-Preserving Surgery for Rectal Cancer at National Comprehensive Cancer Network Centers. Annals of Surgery. 2009 Aug;250(2):260-7.
Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer. Journal of Clinical Oncology. 2009 Jan;27(1):100-5.   PMCID: PMC 2645095
Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol. 2009 Oct;56(4):609-16.   PMCID: PMC2791191
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009 May 15;115(10):2081-91.   PMCID: PMC2875773
Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008 Sep;26(5):555-9.
Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC. Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. Journal of Clinical Oncology. 2008 Dec;26(34):5553-60.
Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox E, Uzzo RG. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology. 2008 Jul;72(1):138-42.
Wong YN. Financial Consequences of Improved Treatments for Colorectal Cancer. Semin Colon Rectal Surg. 2008 Dec;19(4):247-52.   PMCID: PMC2739418
Abraham N, Wan F, Montagnet C, Wong YN, Armstrong K. Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines. Journal of Urology. 2007 Jul;178(1):82-7.
Grusenmeyer PA, Wong YN. Interpreting the economic literature in oncology. Journal of Clinical Oncology. 2007 Jan;25(2):196-202.
Litwin S, Wong YN, Hudes G. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Statistics in medicine. 2007 Oct 30;26(24):4400-15.
Wong Y-N, Change W-C, Clapper M, Engstrom PE. Chemoprevention of colorectal cancer. In: Saltz LB, editor. Colorectal cancer : evidence-based chemotherapy strategies. Totowa, N.J.: Humana Press; 2007. p. 33-49.
Wong YN, Chang WC, Clapper M, Engstrom PF. Chemoprevention of colorectal cancer. In: Saltz LB, editor. Colorectal cancer : evidence-based chemotherapy strategies. Totowa, N.J.: Humana Press; 2007. p. 33-50.
Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K. Survival associated with treatment vs observation of localized prostate cancer in elderly men.[see comment]. Jama. 2006 Dec 13;296(22):2683-93.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Yu-Ning Wong Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Wednesday, September 06, 2017